A consortium of University of Oslo, The International AIDS Vaccine Initiative (IAVI) and the Translational Health Science and Technology Institute (THSTI) has been granted 19.09 MNOK (about U.S. $2.2M) for a period of three years from the Research Council of Norway through the GLOBVAC (Global Health Vaccination and Research) program for the development of broadly neutralizing antibodies as HIV prevention products. Teams on three continents will work to engineer and optimize antibodies to extend their half-life, an improvement designed to increase the duration of antibody activity and potentially lead to longer intervals between protective doses. The consortium is led by UiO.
The program is headed by Jan Terje Andersen, associate professor at the University of Oslo and leader of The Laboratory of Adaptive Immunity and Homeostasis at the Department of Immunology at Oslo University Hospital.
Press release (published on the IAVI home page):
University of Oslo, IAVI, and THSTI to Develop HIV Broadly Neutralizing Antibodies as a Prevention Product for Affordable Global Access
New articles (in Norwegian):
From Dagens medisin:
Får millioner til å forske på hiv
From national newspaper VG:
Millioner til forskning på hiv-medisin for kvinner
Home page of Jan Terje Andresen's research group:
The Laboratory of Adaptive Immunity and Homeostasis
The Laboratory of Adaptive Immunity and Homeostasis on social media: